[Lab] split one vial across PeptideMeter and VendorInvestigate — 98.4% and 97.2%
Posting this because the title is the whole finding — split one vial across PeptideMeter and VendorInvestigate — 98.4% and 97.2% — and a number without its method is a rumour. 98.4% and 97.2%. Those are measured, not estimated, and not rounded up in my favour. The distribution matters more than the mean. In the trial…
This is the fifth "should I go up" post today and they are all welcome — but no member here can answer it for you.
This is the fifth "should I go up" post today and they are all welcome — but no member here can answer it for you.
quiet_moderator is right that the two molecules are not interchangeable. There is no published conversion and the ones circulating are invented.
[removed by moderator]
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
the appetite effect is blunter than sema, in a good way, most weeks
Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.
The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.